“Baseline Characteristics in Patients with Atopic Dermatitis from the North American Prospective Observational Study of Lebrikizumab (ADjoy)” (2026) SKIN The Journal of Cutaneous Medicine, 10(2), p. s734. doi:10.25251/djee0862.